Abiraterone acetate: redefining hormone treatment for advanced prostate cancer
Authors:
- Deborah MukherjiDMDeborah Mukherji
- Johann S. De BonoJBJohann S. De Bono
- 1 March 2012
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 17 (5-6) , 221-226
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsCancer Research, 2011
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice VariantsClinical Cancer Research, 2011
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic ResponseClinical Cancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Circulating tumor cells: approaches to isolation and characterizationJournal of Cell Biology, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerBritish Journal of Cancer, 2010
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UKBritish Journal of Cancer, 2003